文献速递帕金森病与运动障碍

帕金森病发病年龄的全基因组关联分析与荟萃分析:来自COURAGE-PD联盟的证据

Genome-wide Association and Meta-analysis of Age at Onset in Parkinson Disease: Evidence From the COURAGE-PD Consortium.
PubMed 文献 · Neurology · 2022-05-26

本研究对COURAGE-PD联盟30个人群的帕金森病发病年龄全基因组关联研究进行荟萃分析,并与国际帕金森病遗传学联盟数据集合并。COURAGE-PD纳入8535例患者,未发现全基因组显著位点,但证实TMEM175变异与发病年龄相关;合并后总样本25950例,鉴定出SNCA和新型BST1两个全基因组显著信号。

要点

  • COURAGE-PD联盟纳入8535例帕金森病患者,发病年龄遗传力估计为0.083(SE=0.057)。
  • COURAGE-PD数据证实TMEM175变异与帕金森病发病年龄相关(rs34311866:β=0.477,p=0.0185)。
  • COURAGE-PD与IPDGC合并分析(N=25950)发现SNCA和新型BST1位点达全基因组显著。

核心结论

  • 本研究进一步细化了4号染色体上帕金森病发病年龄的遗传结构,将BST1鉴定为新的发病年龄相关位点。
  • 这些发现为开发延迟帕金森病发病的治疗方法开辟了新方向。

研究设计与样本

  • 对COURAGE-PD联盟30个以欧洲血统为主人群的帕金森病发病年龄全基因组关联研究进行荟萃分析。
  • 随后将本研究与IPDGC汇编的最大公开欧洲血统数据集合并分析。
  • COURAGE-PD队列共纳入8535例帕金森病患者(91.9%欧洲人,9.1%东亚人)。

主要发现

  • COURAGE-PD数据集平均发病年龄为58.9岁(SD=11.6),女性占40.2%。
  • COURAGE-PD中发病年龄遗传力估计为0.083(SE=0.057)。
  • COURAGE-PD中无位点达到全基因组显著性(p<5×10^-8)。
  • COURAGE-PD证实TMEM175变异与发病年龄相关,达Bonferroni校正名义显著水平(p<0.025):rs34311866的β(SE)=0.477(0.203),p=0.0185。
  • COURAGE-PD与IPDGC合并分析(Ntotal=25950)鉴定出4号染色体上2个全基因组显著关联信号:SNCA位点(rs983361:β(SE)=0.720(0.122),p=3.13×10^-9)和新型BST1位点(rs4698412:β(SE)=-0.526(0.096),p=4.41×10^-8)。

局限性

  • COURAGE-PD数据集中女性代表性不足(40.2%)。
  • COURAGE-PD中发病年龄遗传力估计为0.083(SE=0.057)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Considerable heterogeneity exists in the literature concerning genetic determinants of the age at onset (AAO) of Parkinson disease (PD), which could be attributed to a lack of well-powered replication cohorts. The previous largest genome-wide association studies (GWAS) identified SNCA and TMEM175 loci on chromosome (Chr) 4 with a significant influence on the AAO of PD; these have not been independently replicated. This study aims to conduct a meta-analysis of GWAS of PD AAO and validate previously observed findings in worldwide populations. METHODS: A meta-analysis was performed on PD AAO GWAS of 30 populations of predominantly European ancestry from the Comprehensive Unbiased Risk Factor Assessment for Genetics and Environment in Parkinson's Disease (COURAGE-PD) Consortium. This was followed by combining our study with the largest publicly available European ancestry dataset compiled by the International Parkinson Disease Genomics Consortium (IPDGC). RESULTS: The COURAGE-PD Consortium included a cohort of 8,535 patients with PD (91.9%: Europeans and 9.1%: East Asians). The average AAO in the COURAGE-PD dataset was 58.9 years (SD = 11.6), with an underrepresentation of females (40.2%). The heritability estimate for AAO in COURAGE-PD was 0.083 (SE = 0.057). None of the loci reached genome-wide significance (p < 5 × 10-8). Nevertheless, the COURAGE-PD dataset confirmed the role of the previously published TMEM175 variant as a genetic determinant of the AAO of PD with Bonferroni-corrected nominal levels of significance (p < 0.025): (rs34311866: β(SE)COURAGE = 0.477(0.203), p COURAGE = 0.0185). The subsequent meta-analysis of COURAGE-PD and IPDGC datasets (Ntotal = 25,950) led to the identification of 2 genome-wide significant association signals on Chr 4, including the previously reported SNCA locus (rs983361: β(SE)COURAGE+IPDGC = 0.720(0.122), p COURAGE+IPDGC = 3.13 × 10-9) and a novel BST1 locus (rs4698412: β(SE)COURAGE+IPDGC = -0.526(0.096), p COURAGE+IPDGC = 4.41 × 10-8). DISCUSSION: Our study further refines the genetic architecture of Chr 4 underlying the AAO of the PD phenotype through the identification of BST1 as a novel AAO PD locus. These findings open a new direction for the development of treatments to delay the onset of PD.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Grover S, Kumar Sreelatha AA, Pihlstrom L, et al. Genome-wide Association and Meta-analysis of Age at Onset in Parkinson Disease: Evidence From the COURAGE-PD Consortium. Neurology. 2022. PMID: 35970579. doi:10.1212/WNL.0000000000200699

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。